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Background: Around 30% Parkinson’s disease (PD) patients develop impulse control
disorders (ICDs) to D2/3 dopamine agonists and, to a lesser extent, levodopa. We aim to
investigate striatal dopaminergic function in PD patients with and without ICD.
Methods: PubMed, Science Direct, EBSCO, and ISI Web of Science databases were
searched (from inception to March 7, 2018) to identify PET or SPECT studies reporting
striatal dopaminergic function in PD patients with ICD (ICD+) compared to those without
ICD (ICD–). Studies which included drug naïve patients, explored non-pharmacological
procedures (e.g., deep brain stimulation), and those using brain blood perfusion or
non-dopaminergic markers were excluded. Standardized mean difference (SDM) was
used and random-effect models were applied. Separate meta-analyses were performed
for dopamine transporter level, dopamine release, and dopamine receptors availability in
the putamen, caudate, dorsal, and ventral striatum.
Results: A total of 238 studies were title and abstract screened, of which 19 full-texts
were assessed. Nine studies (ICD+: N = 117; ICD–: N = 175 patients) were included
in the analysis. ICD+ showed a significant reduction of dopamine transporter binding in
the putamen (SDM = −0.46; 95% CI: −0.80, −0.11; Z = 2.61; p = 0.009), caudate
(SDM=−0.38; 95% CI:−0.73, −0.04; Z = 2.18; p= 0.03) and dorsal striatum (SDM=
−0.45; 95% CI: −0.77, −0.13; Z = 2.76; p = 0.006), and increased dopamine release
to reward-related stimuli/gambling tasks in the ventral striatum (SDM = −1.04; 95%
CI: −1.73, −0.35; Z = 2.95; p = 0.003). Dopamine receptors availability did not differ
between groups. Heterogeneity was low for dopamine transporter in the dorsal striatum
(I2 = 0%), putamen (I2 = 0%) and caudate (I2 = 0%), and pre-synaptic dopamine
release in the dorsal (I2 = 0%) and ventral striatum (I2 = 0%); heterogeneity was high
for dopamine transporter levels in the ventral striatum (I2 = 80%), and for dopamine
receptors availability in the ventral (I2 = 89%) and dorsal (I2 = 86%) striatum, putamen
(I2 = 93%), and caudate (I2 = 71%).
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Conclusions: ICD+ patients show lower dopaminergic transporter levels in the dorsal
striatum and increased dopamine release in the ventral striatumwhen engaged in reward-
related stimuli/gambling tasks. This dopaminergic imbalance might represent a biological
substrate for ICD in PD. Adequately powered longitudinal studies with drug naïve
patients are needed to understand whether these changes may represent biomarkers
of premorbid vulnerability to ICD.
Keywords: Parkinson’s disease, impulse control disorder, dopamine, PET, SPECT, transporter, receptors, meta-
analysis
INTRODUCTION
Impulse control disorders (ICD), such as pathological gambling,
hypersexuality, binge-eating, and compulsive shopping are
diagnosed in around 30% of patients with Parkinson’s disease
(PD) (1–4).
ICDs are considered a complication of D2/3 dopamine agonist
treatment and, to a lesser extent, levodopa (5). This is evident
from studies showing higher ICD rates in medicated PD patients
compared to healthy controls (2, 3, 6, 7). Although ICD rates
have not been directly compared between medicated and drug
naïve PD patients, other studies have shown that rates in drug
naïve PD patients do not differ from healthy controls (8, 9).
There are also retrospective case reports (10–12) and prospective
studies (13–15) showing that in some cases ICDs onset (10–
12, 14, 15) and their reduction or resolution (10, 13, 16) covary
with dopaminergic treatment.
Preclinical animal studies provide further evidence of a
modulatory effect of dopamine agonists on impulsivity using
delay discounting paradigms. In these paradigms, impulsivity
results in a behavioral preference for an immediate (smaller)
reward over a delayed (larger) reward. However, the direction
of the effect of dopamine on the reward system is inconsistent.
For example, some studies showed lower levels of impulsivity on
1 and 2 mg/kg doses of d-amphetamine (17, 18) whereas others
report increased impulsivity in rats treated with similar or higher
doses (e.g., 0.8, 1, 1.20, 3.2 mg/kg) (19–21) or no effects (21, 22).
Studies in healthy volunteers show a modulatory effect of
dopamine agonists on impulsivity; however, like rodent studies
previously mentioned, the direction of the effect is unclear, in
that some studies report increased impulsivity while other ones
show decreased impulsivity to dopamine agonists. For example,
d-amphetamine decreases impulsive behavior on the Stop task
and in the Go/no Go task (measured as Stop reaction time
and number of false alarms), and decreases delay discounting
(23). However, other dopaminergic agents such as levodopa
and pramipexole increase impulsivity on delay discounting and
gambling tasks (24, 25).
In summary, evidence from preclinical rodent studies and
healthy volunteers indicate that dopamine agonists modulate the
reward system and impulsivity, but the direction of the effect is
not clear. This implies that impulsivity is modulated by a complex
interplay of dopamine activity across a network of systems,
and dopamine agonists disrupt the balance between brain areas
modulating impulsivity.
In the first stages of PD, the function of ventral striatum
is relatively more preserved than the dorsal striatum (26).
Therefore, the dopaminergic treatment dose required to restore
motor dorsal striatal dopaminergic levels may overstimulate the
relatively intact ventral striatum (27). This hyperdopaminergic
state may promote an abnormal activity in the connected cortico-
striatal cognitive and limbic pathways that mediate reward-
related behavior (28). As a consequence, the control of goal-
directed behavior is impaired, facilitating ICD development.
If ICDs in PD are linked to the disruption of the equilibrium
in dopamine activity across ventral and dorsal striatum, then
brain positron emission tomography (PET) and single-photon
emission computed tomography (SPECT) can provide a direct
measurement of putative dopaminergic differences between PD
with and without ICDs. These nuclear medicine techniques
use molecular imaging to assess biochemical, neurochemical, or
pharmacological processes in the brain. For example, changes in
neurotransmission can be detected using radiotracers with high
affinity for dopamine receptors.
When a radiotracer is injected, it competes with dopamine
for binding to free dopamine receptors. Thus, if dopamine is
released endogenously, radiotracer binding can therefore be used
as a marker for dopamine release (29). According to the binding
affinity and the type of radiotracer, it is possible to investigate
the nature of the dopaminergic dysfunction, whether linked to
dopamine release, dopaminergic re-uptake in the presynaptic
terminals, and D2/3 post-synaptic receptors availability. The
spatial resolution of current PET and SPECT machines allow
separate assessment of the dorsal and ventral striatal regions, and
their components (i.e., putamen, caudate).
A limitation of the PET and SPECT studies of ICD in PD
published so far is the small sample size, with the largest study
including 21 PD patients with ICD and 68 without ICD (30) and
the smallest including 7 PD patients with ICD and 7 without
ICD (31). Small sample sizes are not surprising, given the high
cost of PET and SPECT exams. Moreover, variability in clinical
and demographic characteristics, types of tracer, protocols of
analysis, and scanners makes the comparison between studies
difficult.
A meta-analytic approach can overcome these limitations.
Low powered studies can be combined and differences in striatal
dopaminergic function between PD patients with and without
ICD estimated with a higher reliability. To the best of our
knowledge, no previous meta-analysis has been published on this
topic.
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Therefore, the objective of this study was to investigate
differences in dopaminergic function in the striatum in PD
patients with and without ICD. To this aim, we systematically
reviewed and meta-analyzed PET and SPECT based reports on
dopamine transporter level, presynaptic dopamine release, and
post-synaptic D2/3 receptors availability in the ventral and dorsal
striatum.
MATERIALS AND METHODS
Search Strategy
The PubMed, Science Direct, EBSCO, and ISI Web of Science
databases were searched for peer-reviewed studies on PET or
SPECT striatal dopaminergic function in PD-related ICD and
published from database inception until the 7th of March 2018.
The following search string was used: “[(Parkinson’s disease
OR Parkinson) AND (impulse control disorders OR impulse
control disorder OR impulsive compulsive behaviors OR
impulsive compulsive behaviors OR impulsive compulsive
behavior OR impulsive compulsive behavior OR ICD OR ICB
OR hypersexuality OR gambling OR buying OR shopping OR
eating)] AND (Positron emission tomography OR PET OR
Single Photon Emission Computed Tomography OR SPECT OR
SPET OR DaTSCAN).” A total of 384 papers were identified.
After the exclusion of duplicates, 238 papers went through title
and abstract screening. Two authors (AM, DDL) independently
screened titles and abstracts using Rayyan software (32) and 17
papers were included in the full-text screening. The reference lists
of these papers were manually searched for additional studies
missed in the databases search, and two relevant papers were
included at this stage. Two authors (AM, DDL) independently
evaluated the 19 papers selected for full-text examination and
disagreements were planned to be resolved via discussion with a
third author (ST). However, there was 100% agreement between
the two authors. Nine studies were included for quantitative
analysis (Figure 1).
Selection Criteria
Studies were included if they met the following inclusion
criteria: (i) PET or SPECT study; (ii) PD patients without ICD
(ICD–) compared with PD patients with ICD (ICD+); (iii) data
reported for at least one striatal region; (iv) independence of the
sample. Therefore, if a study sample was reported in multiple
publications, only the study with the largest sample was included.
We excluded reviews, case studies, commentaries, letters,
abstracts and dissertations, conference papers, and postal
surveys. Studies including drug naïve PD patients were excluded,
as we were interested on ICD developed after dopamine
replacement treatment (DRT) initiation. Moreover, drug naïve
PD patients represent a different sample than those treated with
DRT, as the former have shorter PD duration, and are not
chronically exposed to DRT. Therefore, dopaminergic systems
may be affected and stimulated differently in medicated and
non-medicated PD patients.
Studies in which PD patients underwent deep brain
stimulation (DBS) were also excluded, as ICDs may either
improve or develop after DBS (33). Finally, studies using
measures of brain blood perfusion were excluded, as they do not
explore striatal dopaminergic functioning. Similarly, we excluded
studies with non-dopaminergic markers.
Data Extraction
Corresponding authors of four studies (30, 34–36) were
contacted for exact data. Data reported as median and range
(37) were converted to mean and SD, as proposed by Hozo et al.
(38). When standard error was reported, it was converted to SD
(31, 39). Two authors (AM, DDL) independently extracted the
following demographic and clinical data: sample size, sex, age
at evaluation, age at PD onset, PD duration, education (years),
Hoehn and Yahr (H&Y) stage, Unified PD Rating Scale motor
section (UPDRS-III) ON-medication, depression, antidepressant
use, antipsychotic use, number of patients under dopamine
agonist treatment, dopamine agonist levodopa equivalent daily
dose (LEDD, mg), levodopa LEDD, total LEDD, ICD screening
tool, and ICD type. Methodological characteristics of the
included studies were also extracted: imaging technique (i.e.,
PET or SPECT), type of tracer, reference region, imaging
approach, radiotracer delivery method, drug delivered prior to
scan, outcomemeasure, and striatal division and subdivision that
was examined (i.e., ventral striatum, dorsal striatum, putamen,
caudate).
The outcomes measures were the differences in the
dopaminergic imaging parameters (e.g., binding potentials)
between PD patients with and without ICD in striatal areas (i.e.,
ventral striatum, dorsal striatum, putamen, caudate).
Data Analysis
Separate meta-analyses were performed for studies focusing on
dopamine transporter level, dopamine release (presynaptic), and
dopamine receptors availability (postsynaptic) in the ventral
striatum, dorsal striatum, putamen, and caudate. Data were
analyzed using ReviewManager v5.3 (40). Standardized mean
difference (SMD) was used as effect size measure, with values
around 0.2, 0.5, and 0.8 considered as small, moderate, and large,
respectively (41). Heterogeneity between studies was calculated
by the I2 value with percentages around 25, 50, and 75 considered
as low, moderate, and high, respectively (42). As PD samples
may vary in their clinical (e.g., H&Y stage, UPDRS scores)
and demographic characteristics (e.g., age, sex), a random-effect
model was applied.
Sensitivity analysis was performed by excluding studies clearly
stating current antipsychotic or antidepressant use, as these
drugs may affect dopamine receptor binding potential (43) or
DAT uptake (44). As the number of studies was low, we lacked
the power for conducting moderator analysis (45), or visual
inspections of funnel plots for publication bias (46). A p < 0.05
was used as statistical significance threshold for all the analyses.
RESULTS
Demographic, clinical and methodological characteristics of the
117 ICD+ and 175 ICD– PD patients reported in the nine studies
included in the meta-analysis are reported in Tables 1, 2.
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FIGURE 1 | PRISMA diagram of the study (www.prisma-statement.org). ICD, impulse control disorder; ORs, odds ratios; PET, positron emission tomography; SPECT,
single-photon emission computed tomography.
There was heterogeneity on the procedure to assess ICD across
studies. ICDs were diagnosed either with a clinical interview
based on the Diagnostic and Statistical Manual of Mental
Disorders fourth edition text revision (DSM-IV-TR) (34–37, 44,
48), the Diagnostic and Statistical Manual of Mental Disorders
fifth edition (DSM 5) (39) criteria or with the Questionnaire for
Impulsive-Compulsive Disorders in PD—Rating Scale (QUIP-rs)
(30). In four studies, the clinical interview followed the South
Oaks gambling screen (SOGS) (34, 35), Gambling Symptom
Assessment Scale (G-SAS) (31), QUIP-rs (36), and Sexual
Addiction Screening test (35). In the paper of Steeves et al.
(31), no specific information was provided on criteria for
diagnosing ICDs apart from the use of SOGS for pathological
gambling.
All patients were under DRT. In seven studies there were no
between-group differences in total or dopamine agonist LEDD
(31, 34, 36, 37, 39, 44, 48). One study reported a higher number
of patients under dopamine agonist, however total LEDD and
dopamine agonist doses were comparable between ICD+ and
ICD– groups (30). In one study ICD+ had higher levodopa
LEDD than ICD– (35).
One study divided the ICD+ group in single andmultiple ICD
subgroups (39). As the comparison between single and multiple
ICD was not relevant for our meta-analysis, means and SDs of
the subgroups were merged by calculating the pooled means and
SDs.
Six studies provided results in the left/right (30, 34, 37, 39, 44,
48) and/or anterior/posterior striatal sub-regions (37); data from
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these studies were merged by calculating the pooled means and
SDs.
Seven studies provided means and SDs for putamen and
caudate separately (30, 35–37, 39, 44, 48). For these studies,
putamen and caudate measures were merged to generate a
measure of the whole dorsal striatum, according to Howes et al.
(43). To this aim, the means of the dopaminergic index in
the putamen and caudate were weighed by their volumes to
reflect the larger contribution of the putamen compared to the
caudate, and averaged (43). Since none of the studies reported
the putamen and caudate anatomical volumes, we used those
used by Howes et al. (43) and derived from healthy adults
(n = 34, mean age = 32.5 years, SD = 8.8 years; mean, SD
mm3 volume: putamen = 8805, 994; caudate = 5562, 865). SD
was calculated accounting for the dependency of measures, by
assuming a between-measures correlation of r= 0.5 in the striatal
sub-regions. To test whether the whole dorsal striatum measure
might have concealed differences in its sub-regions, analyses were
repeated considering the putamen and caudate separately.
According to the radiotracer and the imaging approach
used, studies were categorized as investigating (i) dopamine
transporter level (30, 34, 37, 44, 48), (ii) dopamine release (31,
39), and (iii) dopamine receptors availability (31, 35, 36, 39).
Information about radiotracers used in the studies included in
the meta-analysis is reported in Table 3.
In the dopamine transporter level subgroup, three studies (30,
34, 44) used [123I]FP-CIT, a SPECT radiotracer with high affinity
for DAT and modest affinity for the serotonin transporter (47);
one study (48) used the [18F]FP-CIT radiotracer, which has also
cross-affinity to serotonin transporter but a better contrast than
[123I]FP-CIT (56); and one study (37) used [18F]fluorodopa,
which is a marker of both dopaminergic re-uptake and dopamine
synthesis (57).
The pre-synaptic dopamine release subgroup included two
studies (31, 39) using [11C]raclopride, which is a competitive
D2/3 antagonist sensitive to changes in endogenous dopamine
levels (53). Both studies (31, 39) used a two PET sessions design,
with one baseline scan [i.e., control task (31), neutral cues visual
exposure (39)] and one scan during the experimental condition
[i.e., gambling task (31), reward cues visual exposure (39)]. The
binding potential in baseline condition is a measure of basal
level of receptor availability. Conversely, the change in binding
potential between baseline and experimental conditions is an
indirect measure of alteration in striatal dopamine concentration
due to pre-synaptic dopaminergic release. A decrease in binding
potential in comparison to baseline is associated with increase in
dopamine, while an increase in binding potential in comparison
to baseline is associated with a dopamine decrease (53).
Therefore, for the pre-synaptic dopamine release studies (31,
39), the outcome was the percentage [11C]raclopride binding
potential reduction when comparing the experimental and
baseline conditions.
Finally, the post-synaptic dopamine receptors availability
subgroup included one study (35) with [11C]-(+)-PHNO, a
D3-preferring D2/3 receptor ligand, and one study (36) with
[18F]fallypride, which is one of the high affinity D2/3 receptor
ligands that allow quantification of both striatal and extrastriatal
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TABLE 2 | Methodological characteristics of the studies included in the meta-analysis.
References Imaging
technique
Type of tracer Reference
region
Imaging
approach
Radiotracer
delivery
method
Drug delivered
prior scan
ON/OFF Withdrawal period
Cilia et al. (34) SPECT [123I]FP-CIT Occipital cortex Single scan Intravenous
injection
Thyroid blockade
(oral Lugol solution
10–15mg)
30-40min before
the injection
OFF Overnight withdrawal of
dopaminergic
medications
Joutsa et al. (37) PET [18F]fluorodopa Occipital cortex Single scan Bolus
injection
Carbidopa 150mg
1h before the scan
OFF At least 12 h drug
discontinuation (>24 h
for slow-release
medications)
Lee et al. (48) PET [18F]FP-CIT Cerebellum Single scan Bolus
injection
NO OFF At least 12 h withdrawal
of all PD medications
Payer et al. (35) PET [11C]-(+)-PHNO Cerebellum Single scan Bolus
injection
NO OFF At least 8 h withdrawal of
levodopa (current DA use
was an exclusion criteria)
Premi et al. (30) SPECT [123I]FP-CIT Occipital lobe Single scan Intravenous
injection
KClO4 800mg
30min before the
injection
NR NR
Stark et al. (36) PET [18F]fallypride Cerebellum Three emissions
scans
Bolus
injection
NO OFF Washout was at least
40 h for DA and 16 h for
levodopa
Steeves et al. (31) PET [11C]raclopride Cerebellum Two scans in two
separate days within
2 weeks, in
randomized order:
baseline; gambling
task
Ten mCi
injections
NO OFF 12–18 h overnight
withdrawal of PD
medications
Voon et al. (44) SPECT [123I]FP-CIT Occipital lobe Single scan Slow
intravenous
injection
Thyroid blockade
(oral potassium
iodate) 24h prior to
the study
ON NO
Wu et al. (39) PET [11C]raclopride Cerebellum Two scans in 2
separate weekdays
mornings: neutral
stimuli;
reward-related
stimuli
Bolus
injection
NO OFF 12 h withdrawal of PD
medications
DA, dopamine agonist; mCi, millicurie; PD, Parkinson’s disease; PET, positron emission tomography; SPECT, single-photon emission computed tomography.
binding. Two studies (31, 39) with [11C]raclopride were also
included in the post-synaptic dopamine receptors availability
analysis; for these studies the outcome was the value reported for
the baseline conditions.
A total of 292 subjects were included in the meta-analysis, 117
were PD patients with ICD (age range: 45–72 years; PD duration:
1.9–14.3 years; H&Y: 2–3; UPDRS-III score ON medication:
14.2–41) and 175 were PD patients without ICD (age: 51–74
years; PD duration: 1–9.9 years; H&Y stage: 1.9–3; UPDRS-III
score ON medication: 14.6–49) (Table 1).
Four meta-analyses were performed for the dopamine
transporter levels in the ventral striatum, dorsal striatum,
putamen, and caudate. Two meta-analyses were performed for
the pre-synaptic dopamine release in the ventral and dorsal
striatum; the putamen and caudate were not explored for this
outcome, because only one study provided separate values for
these two structures (39). Four meta-analyses were performed for
the post-synaptic dopamine receptors availability in the ventral
striatum, dorsal striatum, putamen, and caudate. Results of the
meta-analyses are provided in Table 4.
Dopamine Transporter Levels
Compared to the ICD– group, tracer binding in the ICD+ group
was significantly reduced in the dorsal striatum (SDM = −0.45;
95% CI: −0.77, −0.13; Z = 2.76; p = 0.006) but not in the
ventral striatum (SDM = −0.91; 95% CI: −2.10, 0.27; Z =
1.51; p= 0.13). When dorsal striatum sub-regions were analyzed
separately, both putamen (SDM=−0.46; 95% CI:−0.80,−0.11;
Z = 2.61; p= 0.009) and caudate (SDM=−0.38; 95% CI:−0.73,
−0.04; Z = 2.18; p = 0.03) tracer bindings were significantly
reduced in the ICD+ vs. ICD– (Figure 2, Table 4).
Heterogeneity was low for the dorsal striatum (χ2 = 1.99,
p = 0.74, I2 = 0%), putamen (χ2 = 1.43, p = 0.70, I2 =
0%), and caudate (χ2 = 1.79, p = 0.62, I2= 0%). However,
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TABLE 3 | Radiotracers used in studies included in the meta-analysis.
Type of
tracer
Study Function and
characteristics
[123I]FP-CIT Cilia et al.
(34); Premi
et al. (30);
Voon et al.
(44)
SPECT radiotracer with high
affinity for DAT (49) and
serotonin transporter (50)
[18F]FP-CIT Lee et al. (48) SPECT radiotracer with high
affinity for DAT with high
signal-to-noise ratio and
kinetics (51)
[18F]fluorodopa Joutsa et al.
(37)
PET radiotracer for both
presynaptic dopamine
metabolism (synthesis) (52)
and striatal dopamine
uptake
[11C]raclopride Steeves et al.
(31); Wu et al.
(39)
PET selective D2/D3
antagonist sensitive to
changes in endogenous
dopamine levels; it can be
used to assess both basal
levels of receptor availability
and changes in availability
caused by alterations in
striatal dopamine
concentration (53)
[11C]-(+)-
PHNO
Payer et al.
(35)
PET ligand with high affinity
and selectivity for D3
receptors (54)
[18F]fallypride Stark et al.
(36)
PET ligand with high affinity
to D2/3 receptors in striatal
and extrastriatal regions (55)
DAT, dopamine transporter; PET, positron emission tomography; SPECT, single-photon
emission computed tomography.
heterogeneity in the ventral striatum was high (χ2 = 10.14, p =
0.006, I2 = 80%; Figure 2). Sensitivity analysis was performed
by excluding Premi et al. (30), which enrolled 12 patients under
anti-depressant treatment that was suspended 3 weeks before
assessment. Exclusion of Premi et al. (30) did not change overall
effect size for dorsal striatum (SDM = −0.58; 95% CI: −0.99,
−0.16; Z = 2.73; p = 0.006), putamen (SDM = −0.54; 95% CI:
−1.02, −0.06; Z = 2.23; p = 0.03), and caudate (SDM = −0.54;
95% CI: −1.02, −0.07; Z = 2.24; p = 0.03), and heterogeneity
(dorsal striatum: χ2 = 1.07, p = 0.78, I2 = 0%; putamen: χ2 =
1.19, p= 0.55, I2 = 0%; caudate: χ2 = 0.87, p= 0.65, I2 = 0%).
Pre-synaptic Dopamine Release
ICD+ group, compared to the ICD– group, showed reduced
binding in the ventral striatum in response to reward-related
stimuli/gambling task (SDM=−1.04; 95%CI:−1.73,−0.35; Z=
2.95; p = 0.003), but not in the dorsal striatum (SDM = −0.36;
95% CI:−1.01, 0.28; Z = 1.10; p= 0.27; Figure 3, Table 4).
Heterogeneity was low for both ventral (χ2 = 0.22, p = 0.64,
I2 = 0%) and dorsal (χ2 = 0.42, p= 0.52, I2 = 0%) striatal regions
(Figure 3).
Post-synaptic Dopamine Receptors
Availability
Post-synaptic dopamine receptor bindings potentials did not
differ between ICD+ and ICD– groups in the ventral striatum
(SDM = −1.29; 95% CI: −2.68, 0.10; Z = 1.82; p = 0.07), dorsal
striatum (SDM = −0.69; 95% CI: −1.86, 0.48; Z = 1.16; p =
0.25), putamen (SDM = −1.06; 95% CI: −2.94, 0.81; Z = 1.11;
p= 0.26), and caudate (SDM=−0.59; 95% CI:−1.40, 0.23; Z =
1.41; p= 0.16; Figure 4, Table 4).
Heterogeneity was high in the ventral striatum (χ2 = 26.71, p
< 0.00001, I2 = 89%), dorsal striatum (χ2 = 21.90, p < 0.0001,
I2 = 86%), putamen (χ2 = 28.99, p < 0.00001, I2 = 93%), and
caudate (χ2 = 6.86, p= 0.03, I2 = 71%; Figure 4).
Sensitivity analysis was performed by excluding Payer et al.
(35), which enrolled one patient taking antidepressant. Exclusion
of Payer et al. (13) did not change the overall effect size for the
ventral striatum (SDM = −1.42; 95% CI: −3.54, 0.69; Z = 1.32;
p = 0.19), dorsal striatum (SDM = −0.84; 95% CI: −2.55, 0.86;
Z = 0.97; p = 0.33), putamen (SDM = −1.54; 95% CI: −4.87,
1.80; Z = 0.90; p = 0.37), and caudate (SDM = −0.56; 95%
CI: −1.99, 0.87; Z = 0.77; p = 0.44), and heterogeneity (ventral
striatum: χ2 = 26.58, p < 0.00001, I2 = 92%; dorsal striatum: χ2
= 20.53, p< 0.0001, I2= 90%; putamen:χ2= 25.42, p< 0.00001,
I2 = 96%; caudate: χ2 = 6.86, p= 0.009, I2 = 85%).
DISCUSSION
This is the first systematic review and meta-analysis on
PET/SPECT dopaminergic striatal correlates of ICD in PD. Our
aim was to investigate if striatal dopaminergic function differs
in PD patients with and without ICD. To this aim, we reviewed
and analyzed studies on dopamine transporter levels, presynaptic
dopamine release, and post-synaptic D2/3 receptors availability in
the ventral and dorsal striatum.We found ICD+ to be associated
with (i) lower DAT levels in the dorsal striatum and in its
subdivisions (i.e., putamen, caudate) and (ii) reduced binding
(i.e., increased dopamine release) in the ventral striatum in
response to reward-related stimuli or gambling task, but (iii) no
relationship between ICD+ and striatal post-synaptic receptors
availability in either the dorsal or ventral striatum.
Dopamine Transporter Levels
ICD+ group showed lower dorsal striatumDAT binding than the
ICD– one.
In the striatum, DAT is localized in axon varicosities and
terminals that contain synaptic vesicles, as well as in non-
synaptic region where it regulates and terminates extracellular
dopamine activity (44). Therefore, reduced DAT might reflect
more pronounced dorsal striatal dopaminergic terminal loss,
functional DAT downregulation, or genetically determined lower
membrane expression on otherwise normal neurons (34).
The hypothesis of more severe degeneration of nigrostriatal
projections in ICD+ patients is supported by a recent meta-
analysis of case-control studies showing that the risk of ICD in
PD increases with disease duration and being medicated for PD
(58), two factors that are directly correlated with the amount of
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TABLE 4 | Results of the meta-analysis.
Outcome K N Random-effect model results Heterogeneity
SMD [95% CI] Z p X2 p I2(%)
Dopamine transporter
level–ventral striatum
3 71 −0.91 [−2.10, 0.27] 1.51 0.13 10.14 0.006 80
Dopamine transporter
level–dorsal striatum
5 184 −0.45 [−0.77, −0.13] 2.76 0.006 1.99 0.74 0
Dopamine transporter
level–putamen
4 155 −0.46 [−0.80, −0.11] 2.61 0.009 1.43 0.70 0
Dopamine transporter
level–caudate
4 155 −0.38 [−0.73, −0.04] 2.18 0.03 1.79 0.62 0
Dopamine release–ventral
striatum
2 40 −1.04 [−1.73, −0.35] 2.95 0.003 0.22 0.64 0
Dopamine release–dorsal
striatum
2 40 −0.36 [−1.01, 0.28] 1.10 0.27 0.42 0.52 0
Receptors
availability–ventral striatum
4 107 −1.29 [−2.68, 0.10] 1.82 0.07 26.71 <0.00001 89
Receptors availability–dorsal
striatum
4 107 −0.69 [−1.86, 0.48] 1.16 0.25 21.90 <0.00001 86
Receptors
availability–putamen
3 93 −1.06 [−2.94, 0.81] 1.11 0.26 28.99 <0.00001 93
Receptors
availability–caudate
3 93 −0.59 [−1.40, 0.23] 1.41 0.16 6.86 0.03 71
K, number of studies; N, number of participants; SMD, standardized mean difference; CI, confidence interval. P values below the significance level (p < 0.05) are reported in italics.
nigrostriatal loss. Moderator analysis for these two factors was
not possible, because of the small number of studies included in
the meta-analysis.
The lower DAT binding in ICD+may also reflect medication-
related DAT downregulation, but DAT regulation by DRT was
found to be modest (44, 59). It is unlikely that lower DAT
binding is a compensatory effect of medication, as longitudinal
studies on drug naïve PD patients show that dorsal striatal
DAT downregulation precedes DRT initiation (15, 60). SPECT
findings are further supported by a genetic study showing an
association between ICD in PD and a variant of the dopamine
transporter gene, i.e., 9-repeat allele of the SLC6A3 (61); this
variant results in lower presynaptic DAT expression, reduced
synaptic clearance, and increased DA availability in the synaptic
space (62).
Pre-synaptic Dopamine Release
ICD+ group showed reduced binding potential in ventral but
not dorsal striatumwhen exposed to reward-related cues or when
engaged in a gambling task.
Participants to a gambling task are required to actively choose
options associated either with reward or penalty and process
related feedback. Conversely, in reward-related cues paradigms,
participants passively view neutral or reward-related stimuli (e.g.,
food, erotic pictures, gambling, or shopping related activities)
without any active choice. Albeit being different, these tasks
share neurobiological underpinnings. In pathological gamblers,
reductions of ventral striatal and ventromedial prefrontal cortex
activity have been documented in a gambling task (63) and
reward-related reactivity has been shown to involve the dorsal
lateral prefrontal cortex network (64) that is functionally
connected to the ventral striatum.
[11C]raclopride is sensitive to competition from
endogenously released dopamine to a stimulus, therefore
decreased binding potential found in ICD+ vs. ICD– groups
in response to gambling tasks or rewarding stimuli reflects
increased dopamine release. These findings are in keeping with
functional imaging studies of behavioral and pharmacological
addiction in the general population, whereby monetary and
sexual stimuli elicit the same patterns of striatal activation as
recreational drugs (31, 65). Increased dopamine release during
a gambling task has been reported in pathological gamblers
(66, 67) and it correlates both with gambling severity (68)
and increased excitement levels despite lower performances
(66). This may be the consequence of conditioned response
to the reward-related or gambling cues, although increased
dopaminergic release has been observed also for unconditioned
stimuli (39).Whether the increased dopamine release in the
ventral striatum exists in the premorbid phase therefore
representing a vulnerability factor or it is the consequence of
repeated exposure to gambling or rewarding-related stimulus
(69, 70), to DRT (71), or a combination of these factors (31) is
unknown. Only preclinical models and prospective studies can
address this point.
These findings have important implications, since the
exposure to any reward-related cue (e.g., through advertisement)
may have the potential to increase abnormal dopamine release
in vulnerable PD patients (72), as supported by a study showing
increased dopamine release in single ICD PD patients to reward-
cues not related to their ICD (e.g., gamblers to food-related cues)
(39).
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FIGURE 2 | Forest plots for dopamine transporter levels. Here are reported forest plots for dopamine transporter levels in the ventral striatum (A), dorsal striatum (B),
putamen (C), and caudate (D). Standardized mean difference represents Hedges’s g effect size. The size of the square indicates the weight of the study. The
horizontal line represents the 95% confidence interval. The diamond represents the pooled effect size. Negative effect sizes indicate lower dopamine transporter levels
in PD patients with ICD (ICD+) in comparison to those without ICD (ICD–). ICD, impulse control disorder; PD, Parkinson’s disease.
There are two other neuropharmacological mechanisms that
should be considered. First, in patients treated with dopamine
agonists the activation of presynaptic D2-like presynaptic
autoreceptors in themesolimbic system reduces phasic dopamine
release in the nucleus accumbens (25, 73, 74). Therefore,
reward responsiveness is blunted and risk propensity enhanced
in order to normalize mesolimbic eﬄux (73). Second, reward
detection capacity depends on phasic dopaminergic cell firing.
Phasic dopamine dips encode prediction errors therefore
providing outcome-related feedback which signal the need
of behavioral adjustments as reward contingencies change
(75). In rats, a low dose of monoamine-depleting agent
reserpine administered together with pramipexole, exacerbated
its effects on disadvantageous decision-making without changing
pramipexole-induced decrease in the phasic dopamine release.
This suggests that the effect of dopamine agonist on ICD may
not be caused by changes in phasic dopamine release in the
nucleus accumbens (73). Moreover, dopamine agonists tonically
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FIGURE 3 | Forest plots for dopamine release. Here are reported forest plots for dopamine release in the ventral striatum (A), and in dorsal striatum (B). Standardized
mean difference represents Hedges’s g effect size. The size of the square indicates the weight of the study. The horizontal line represents the 95% confidence interval.
The diamond represents the pooled effect size. Negative effect sizes indicate lower dopamine release in PD patients with ICD (ICD+) in comparison to those without
ICD (ICD–). ICD, impulse control disorder; PD, Parkinson’s disease.
bind to D2 receptors irrespective of phasic changes in firing
(76).
Post-synaptic Dopamine Receptors
Availability
We did not find changes in D2/3 receptors availability between
ICD+ and ICD– PD patients. This finding is, to some extent,
surprising for a number of considerations. Animal PD models
showed increased D3 expression after repeated administration of
DRT (35). A PET study found relationships between higher D3
levels, dopamine release in the ventral striatum, and ICD severity
in people without PD (77). Preclinical rats models of PD shows
that ICD–like behaviors can be triggered by pramipexole (78, 79)
and ropinirole (80, 81), which mainly target D2/3 receptors.
Polymorphisms of D2/3 receptors genes are associated with
addictive behaviors in PD (82), and in the general population
(83). D3 receptor antagonists may block reward seeking in animal
models (84–86).
Different lines of reasoning may explain this apparently
paradoxical finding. Heterogeneity was high for this outcome
in our meta-analysis, and this may reflect differences in the
radiotracers used by the studies we included. However, random
effect model does not assume homogeneity of the effect
and findings should have been robust to heterogeneity. D2/3
receptors localize both to pre-synaptic mesolimbic terminal auto-
receptors and post-synaptic indirect-pathway medium spiny
neurons (36). Therefore, binding of radiotracers may reflect a
mix of pre- and post-synaptic changes (35). Moreover, D2/3
receptors changes have not been universally observed across
the spectrum of maladaptive reward-seeking behavior, where
reductions are notably absent in primary gambling addiction
(36, 87). In individuals with substance dependence there is lower
D2/3 receptors availability than healthy controls (88), but no
differences have been reported in pathological gamblers (66,
67).
Limitations and Future Directions
The main limitation of the present meta-analysis is the
small number of studies included, and consequently the low
statistical power, which impede any definite conclusions on
the mechanisms underlying ICD in PD. The small number of
studies hampered a moderator analysis, which would have added
information on the variables potentially contributing to our
results. Our data suggest that more studies with large numbers
of patients are needed. They should have a longitudinal design
with drug naïve patients, to clarify the causative relations between
striatal dopaminergic changes and ICD, and whether they
are pre-morbid vulnerability traits, or a consequence of DRT.
Current cross-sectional studies may only document associative
links. Future studies should incorporate a healthy control group
(34, 35, 48), as some dopaminergic changes might be age-related
and not directly linked to PD or ICD (89).
PET/SPECT studies on extrastriatal regions, which interact
with the striatum in the control of motivated and addictive
behavior (37, 48), are still scarce, and focus on a range
of different structures, impeding a meta-analysis. The role
of extrastriatal dopaminergic changes should be assessed.
At the time of our literature search, five studies reported
data on extrastriatal regions, including the orbitofrontal (37),
medial orbitofrontal (35), ventromedial prefrontal (48), and left
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FIGURE 4 | Forest plots for post-synaptic receptors availability. Here are reported forest plots for post-synaptic receptors availability in the ventral striatum (A), dorsal
striatum (B), putamen (C), and caudate (D). Standardized mean difference represents Hedges’s g effect size. The size of the square indicates the weight of the study.
The horizontal line represents the 95% confidence interval. The diamond represents the pooled effect size. Negative effect sizes indicate lower receptors availability in
PD patients with ICD (ICD+) in comparison to those without ICD (ICD–). ICD, impulse control disorder; PD, Parkinson’s disease.
anterior cingulate cortex (90), the amygdala (48), substantia
nigra (35), globus pallidus (35, 36), ventral pallidus (35),
thalamus (36), and the midbrain (36, 90). Exploring these
areas would be important, since, e.g., abnormal functioning of
D2/3 midbrain receptors might results in increased dopamine
release (91).
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Since the dopamine system may not be the only player in
ICD development, multi-modal imaging studies should explore
the contribution of serotoninergic systems to ICD in PD
(30, 61, 92).
Finally, ICD in PD was found to be associated with
cognitive (worse set-shifting and reward-related decision-
making), and neuropsychiatric features (increased depression,
anxiety, anhedonia, and impulsivity) (93). The potential
confounding role of these clinical variables should be considered
in future PET/SPECT studies.
CONCLUSIONS
Our meta-analysis showed specific patterns of dopaminergic
dysfunction in the dorsal and ventral striatum in PD patients with
ICD. These changes, which, to some extent, differ from those
in people with ICD but no PD, may reflect either a preexisting
neural trait vulnerability for impulsivity or the expression
of a maladaptive synaptic plasticity under non-physiological
dopaminergic stimulation (30).
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